Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALLAS adjuvant palbociclib in HR+/HER2- early breast cancer
2024-514841-12-00Phase 3Authorised
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised trial of palbociclib in breast cancer (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Invasive disease-free survival (iDFS). Planned start Jul 2024; status: authorised.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514841-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514841-12-00.